{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
megestrol acetate
to a specific field?
Class:
PROTEIN
FERTIRELIN is an analog of luteinizing hormone releasing factor. The drug has been used since 1981 in Japan to treat various types of reproductive failure in cattle.
Status:
Investigational
Source:
NCT02359227: Phase 2 Interventional Completed Heart Failure
(2015)
Source URL:
Class:
PROTEIN
Cenderitide, is a novel chimeric natriuretic peptide(NP) developed by the Mayo Clinic as a potential treatment for heart failure. As a chimeric peptide, cenderitide is a single-chemical entity that possesses two separate functions. Specifically, this novel peptide was engineered unlike native NPs to uniquely co-activate the two particulate guanylyl cyclase (pGC) receptors (pGC-A and pGC-B) so as to take advantage of distinct receptor mediated actions through 3′5′ cyclic guanosine monophosphate (cGMP). The rationale for its design was to achieve the renal-enhancing and antifibrotic properties of dual receptor activation, but without clinically significant hypotension.
Status:
Investigational
Source:
NCT03905707: Phase 3 Interventional Active, not recruiting Short Bowel Syndrome
(2019)
Source URL:
Class:
PROTEIN
Glepaglutide (also known as ZP 1848), a long-acting glucagon-like peptide-2 (GLP-2) analog that was developed for patients with reduced or complete loss of intestinal function. In October 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS). Many people with SBS are dependent on the frequent intake of intravenous fluids and nutrition delivered through a central catheter. Currently, glepaglutide is participating in a phase III clinical trial to determine the safety and efficacy of subcutaneous injection of the drug for the treatment of SBS.
